Trump to Announce New Drug Pricing Deals with Multiple Pharmaceutical Companies
President Donald Trump is set to announce new voluntary drug pricing agreements with nearly a dozen pharmaceutical companies on Monday, continuing his administration's efforts to align U.S. prices with lower international rates under the 'most favored nation' policy. These deals follow previous agreements reached over the past year with firms like Pfizer and Novo Nordisk. The reported discounts will apply primarily in state Medicaid programs and aim to reduce what states pay for outpatient drugs, mirroring foreign pricing models. In exchange, participating companies may be exempt from Medicare discount mandates. While these arrangements could affect corporate profits, they are part of broader efforts by the administration to highlight healthcare affordability ahead of upcoming elections. Pharmaceutical firms have already adjusted their strategies in response to Trump's policies, including shifting manufacturing back to the U.S., expanding direct-to-consumer sales channels, and offering products on platforms like TrumpRx. However, industry groups such as PhRMA argue that other factors—like pharmacy benefit managers—are more responsible for high drug costs.
